Retrospective Cohort Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Mar 28, 2018; 24(12): 1321-1331
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1321
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Cumulative incidence of recurrence curve (A) and Kaplan-Meyer survival curve (B) by number of elevated tumor biomarkers.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Cumulative incidence of recurrence curve (A) and Kaplan-Meyer survival curve (B) by BALAD score.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Cumulative incidence of recurrence curve (A) and Kaplan-Meyer survival curve (B) by BALAD-2 class.
  • Citation: Wongjarupong N, Negron-Ocasio GM, Chaiteerakij R, Addissie BD, Mohamed EA, Mara KC, Harmsen WS, Theobald JP, Peters BE, Balsanek JG, Ward MM, Giama NH, Venkatesh SK, Harnois DM, Charlton MR, Yamada H, Algeciras-Schimnich A, Snyder MR, Therneau TM, Roberts LR. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol 2018; 24(12): 1321-1331
  • URL: https://www.wjgnet.com/1007-9327/full/v24/i12/1321.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v24.i12.1321